M3814

DRUG2 trials

Sponsors

EMD Serono Research & Development Institute, Inc.

Conditions

OncologySmall Cell Lung CancerSolid Tumors

Phase 1

Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)

TerminatedNCT03116971

EMD Serono Research & Development Institute, Inc.Small Cell Lung Cancer

Start: 2017-05-25End: 2018-03-01Updated: 2020-09-16

Study of Avelumab-M3814 Combinations

CompletedNCT03724890

EMD Serono Research & Development Institute, Inc.Oncology, Solid Tumors

Start: 2018-11-27End: 2022-08-17Updated: 2025-04-10

Related Papers

Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors.

2024-02-0511 citations

Phase I crossover study of DNA‐protein kinase inhibitor peposertib in healthy volunteers: Effect of food and pharmacokinetics of an oral suspension

Clinical and Translational Science2023-10-313 citations

Phase 1, open-label, dose-escalation study of M3814 + avelumab ± radiotherapy (RT) in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2019-05-207 citations